Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JAAX | ISIN: US15102K1007 | Ticker-Symbol:
NASDAQ
24.04.25
15:30 Uhr
11,050 US-Dollar
-0,030
-0,27 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CELCUITY INC Chart 1 Jahr
5-Tage-Chart
CELCUITY INC 5-Tage-Chart

Aktuelle News zur CELCUITY Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
01.04.Stifel maintains Celcuity stock Buy rating, $42 target1
01.04.Celcuity projects $2B revenue potential for gedatolisib in second-line breast cancer market1
31.03.Celcuity Inc. - 10-K, Annual Report2
31.03.Celcuity Inc. - 8-K, Current Report1
31.03.Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update55The PIK3CA wild-type cohort of the VIKTORIA-1 Phase 3 trial is on track to report topline data in Q2 2025VIKTORIA-2 Phase 3 remains on track to enroll its first patient in Q2 2025Presented encouraging...
► Artikel lesen
28.03.An Overview of Celcuity's Earnings1
11.12.24Celcuity reports survival data for breast cancer drug2
CELCUITY Aktie jetzt für 0€ handeln
11.12.24Celcuity Inc.: Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium124Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in the advanced setting was 77.3 months Median OS among patients previously treated with...
► Artikel lesen
06.12.24Celcuity Inc. - 8-K, Current Report-
14.11.24Celcuity GAAP EPS of -$0.70 misses by $0.0516
14.11.24Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update131The PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial is 100% enrolled; expect to report topline data for this cohort in late Q1 2025 or Q2 2025Approximately $264 million in cash, cash equivalents...
► Artikel lesen
14.11.24Celcuity Inc. - 10-Q, Quarterly Report-
13.11.24Insights into Celcuity's Upcoming Earnings1
14.08.24Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update151Announced plan to initiate Phase 3 VIKTORIA-2 trial evaluating gedatolisib combined with fulvestrant plus a CDK4/6 inhibitor as first-line treatment for patients with HR+, HER2- advanced breast cancer...
► Artikel lesen
30.05.24Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing183The Phase 3 clinical trial will evaluate gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer who are endocrine therapy resistantReceived...
► Artikel lesen
15 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1